Lane S - Search Results

1

WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation.

Gray JX, McMillen L, Mollee P, Paul S, Lane S, Bird R, Gill D, Saal R, Marlton P. Gray JX, et al. Among authors: lane s. Leuk Res. 2012 Apr;36(4):453-8. doi: 10.1016/j.leukres.2011.09.005. Epub 2011 Oct 2. Leuk Res. 2012. PMID: 21967832

2

A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.

Lane S, Saal R, Mollee P, Jones M, Grigg A, Taylor K, Seymour J, Kennedy G, Williams B, Grimmett K, Griffiths V, Gill D, Hourigan M, Marlton P. Lane S, et al. Leuk Lymphoma. 2008 Mar;49(3):517-23. doi: 10.1080/10428190701817266. Leuk Lymphoma. 2008. PMID: 18297529

3

Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity.

Lane S, Gill D, McMillan NA, Saunders N, Murphy R, Spurr T, Keane C, Fan HM, Mollee P. Lane S, et al. Leuk Lymphoma. 2012 Jun;53(6):1077-83. doi: 10.3109/10428194.2011.642302. Epub 2012 Jan 11. Leuk Lymphoma. 2012. PMID: 22098405 Clinical Trial.

4

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.

Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN. Lane SW, et al. Leuk Lymphoma. 2006 Sep;47(9):1813-7. doi: 10.1080/10428190600632832. Leuk Lymphoma. 2006. PMID: 17064993

5

Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.

Gill S, Lane SW, Crawford J, Cull G, Joske D, Marlton P, Mollee PN, Prince HM, Seymour JF. Gill S, et al. Among authors: lane sw. Ann Hematol. 2008 Sep;87(9):727-34. doi: 10.1007/s00277-008-0488-6. Epub 2008 Apr 10. Ann Hematol. 2008. PMID: 18401583

6

Increased mortality with FLA compared with ADE chemotherapy in high-risk AML.

Lane SW, Marlton P, Mollee PN. Lane SW, et al. Blood. 2006 Dec 1;108(12):3950-1; author reply 3951. doi: 10.1182/blood-2006-06-032680. Blood. 2006. PMID: 17114571 Free article. No abstract available.

7

Palifermin-induced acanthosis nigricans.

Lane SW, Manoharan S, Mollee PN. Lane SW, et al. Intern Med J. 2007 Jun;37(6):417-8. doi: 10.1111/j.1445-5994.2007.01340.x. Intern Med J. 2007. PMID: 17535389 No abstract available.

8

Role of VAD in the initial treatment of multiple myeloma.

Lane SW, Gill D, Mollee PN, Rajkumar SV. Lane SW, et al. Blood. 2005 Nov 15;106(10):3674; author reply 3674-5. doi: 10.1182/blood-2005-07-2610. Blood. 2005. PMID: 16267264 Free article. No abstract available.

9

Hereditary fibrinogen A alpha-chain amyloidosis.

Lane SW, Goodman HJ, Francis L, Bofinger A, Mollee PN. Lane SW, et al. Pathology. 2006 Aug;38(4):380-2. doi: 10.1080/00313020600820823. Pathology. 2006. PMID: 16916739 No abstract available.

10

Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.

Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, Conyers R, Haeusler GM, Hardie C, Jackson C, Lane SW, Middlemiss T, Mollee P, Mulligan SP, Ritchie D, Ruka M, Solomon B, Szer J, Thursky KA, Wood EM, Worth LJ, Yong MK, Slavin MA, Teh BW. Weinkove R, et al. Med J Aust. 2020 Jun;212(10):481-489. doi: 10.5694/mja2.50607. Epub 2020 May 13. Med J Aust. 2020. PMID: 32401360 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,697 results

Search Page

Filters